Macrogenics (MGNX) Stock
Small biotech developing cancer antibody treatments. Here's the price, business snapshot, and what's worth knowing about Macrogenics in October 2026.
MacroGenics, Inc. (MGNX) is a small‑cap biotechnology company focused on antibody-based and bispecific immunotherapies, primarily in oncology. Investors should know the company leverages engineered Fc domains and dual‑affinity platforms to design targeted treatments; its pipeline spans preclinical to later-stage clinical programmes. As a clinical‑stage specialist with a market cap of about $127.7M, MacroGenics’ value is sensitive to trial readouts, regulatory decisions and partnership news. Biotech firms at this stage typically face significant cash burn and may need to raise capital, which can dilute shareholders. Partnerships and licensing deals can reduce commercial risk and provide non‑dilutive funding, but success depends on clinical efficacy and market adoption. This summary is educational, not personal financial advice — returns are not guaranteed and values can fall as well as rise. Investors should consider their risk tolerance and consult a regulated adviser before making decisions.
Macrogenics (MGNX) Stock Forecast
Analyst price target, next 12 months
$10.46
+179.7% vs today's $3.74
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Macrogenics have a consensus 12-month target of $10.46, above the current price of $3.74.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 11 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Macrogenics' stock with a target price of $10.46, indicating good growth potential.
Financial Health
Macrogenics is performing well with strong revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Multiple upcoming trial readouts can materially move the share price; these events are high‑impact but outcomes are binary and can be volatile.
Engineering antibodies
Fc‑engineering and bispecific platforms may create differentiated treatments, though technical and regulatory challenges remain that can delay progress.
Partnerships matter
Collaborations and licensing deals can provide funding and commercial reach, but the benefits depend on execution and market uptake.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
